Targeting Nrf2/ HO ‐1, NF ‐ κ B , and Apoptotic Pathways: Mechanistic Evaluation of Phlorizin Nanoparticles in Diabetic Renal Injury
Clinical and Experimental Pharmacology and Physiology · 2026-05 · 53 (5)
DOI: 10.1111/1440-1681.70129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, online erschienen am 06.05.2026. Verfasst von Ahmed M S Hegazy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia. Hauptthemen laut MEDLINE: Apoptosis, Nanoparticles, Phlorhizin, Diabetic Nephropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Northern Border University.
Abstract (Originalsprache)
Diabetes mellitus (DM) is a chronic metabolic disorder associated with hyperglycemia, dyslipidemia, oxidative stress, inflammation, apoptosis, and renal dysfunction. Although phlorizin (PHL) possesses well‐documented antidiabetic properties, its clinical applicability is limited by poor bioavailability and rapid metabolism, which may restrict its therapeutic efficacy. This study evaluated the therapeutic potential of phlorizin (PHL) and its chitosan nanoparticle formulation (PHL‐CSNPs) in streptozotocin (STZ)‐induced type 1 diabetic rats. Ninety adult male albino rats were randomly divided into six groups ( n = 15 each): non‐diabetic control, non‐diabetic treated with crude PHL, non‐diabetic treated with PHL‐CSNPs, diabetic untreated (STZ‐induced T1DM), diabetic treated with crude PHL, and diabetic treated with PHL‐CSNPs. STZ‐induced T1DM caused significant reductions in serum insulin, body weight gain, renal antioxidant defences, and mitochondrial function, accompanied by marked elevations in fasting blood glucose, dyslipidemia, oxidative stress markers, pro‐inflammatory cytokines, apoptotic markers, and renal fibrotic mediators, as well as pronounced histopathological and ultrastructural kidney damage. In diabetic rats, treatment with PHL‐CSNPs significantly improved insulin levels, glucose homeostasis, and body weight, restored lipid profiles and antioxidant enzyme activities, enhanced mitochondrial respiratory complex activities and ATP production, suppressed NF‐ κ B–mediated inflammation, upregulated Nrf2/HO‐1 signalling, decreased Bax and caspase‐3 levels, increased Bcl‐2 levels, and reduced TGF‐ β 1–mediated fibrosis. Crude PHL provided moderate protective effects but was consistently less effective than the nanoparticle formulation. Importantly, the chitosan nanoparticle formulation markedly enhanced the therapeutic efficacy of PHL, likely by improving its stability, bioavailability, and renal tissue delivery, thereby producing stronger antioxidant, anti‐inflammatory, and anti‐apoptotic effects than crude PHL. Non‐diabetic rats treated with either PHL or PHL‐CSNPs maintained normal metabolic and renal parameters, confirming the safety of the treatments. Histopathological and ultrastructural analyses further confirmed the preservation of renal architecture in PHL‐CSNP–treated diabetic rats. Collectively, this study demonstrates that nanoencapsulation significantly potentiates the biological activity of PHL, providing a clear therapeutic advantage over the crude compound. Overall, these findings demonstrate that PHL‐CSNPs provide superior nephroprotective, antioxidant, anti‐inflammatory, and metabolic benefits, highlighting their potential as a promising therapeutic strategy for managing type 1 diabetes‐induced metabolic and renal complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.
- Community Health Department, Faculty of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia.
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
- Experimental Biochemistry Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
- Editome: Precision Gene Editing Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
- Center for Health Research, Northern Border University, Arar, Saudi Arabia.
ORCID-Profile: Ahmed M S Hegazy, Nasser S Alqahtani, Ayat B Al-Ghafari, Huda A Al Doghaither, Ekramy M Elmorsy, Noha Osama El-Shaer
Förderung
- Northern Border University
Zitieren
APA
Hegazy, A. M. S., Alqahtani, N. S., Al-Ghafari, A. B., Al Doghaither, H. A., Elmorsy, E. M., El-Shaer, N. O., & Abdelhady, D. (2026). Targeting Nrf2/ HO ‐1, NF ‐ κ B , and Apoptotic Pathways: Mechanistic Evaluation of Phlorizin Nanoparticles in Diabetic Renal Injury. Clinical and Experimental Pharmacology and Physiology, 53(5). https://doi.org/10.1111/1440-1681.70129
Vancouver
Hegazy AMS, Alqahtani NS, Al-Ghafari AB, Al Doghaither HA, Elmorsy EM, El-Shaer NO, et al. Targeting Nrf2/ HO ‐1, NF ‐ κ B , and Apoptotic Pathways: Mechanistic Evaluation of Phlorizin Nanoparticles in Diabetic Renal Injury. Clinical and Experimental Pharmacology and Physiology. 2026;53(5). doi:10.1111/1440-1681.70129
BibTeX
@article{Hegazy2026,
author = {Hegazy, Ahmed M S and Alqahtani, Nasser S and Al-Ghafari, Ayat B and Al Doghaither, Huda A and Elmorsy, Ekramy M and El-Shaer, Noha Osama and Abdelhady, Dania},
title = {Targeting Nrf2/ HO ‐1, NF ‐ κ B , and Apoptotic Pathways: Mechanistic Evaluation of Phlorizin Nanoparticles in Diabetic Renal Injury},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2026},
volume = {53},
number = {5},
doi = {10.1111/1440-1681.70129}
}
EUVIMED